Vanguard Capital Management
VTVT icon

Vanguard Capital Management’s vTv Therapeutics VTVT Stock Holding History

Vanguard Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56M Sell
94,463
-14,459
-13% -$501K ﹤0.01% 3232
2026
Q1 		$4.32M Buy
+108,922
New +$3.95M ﹤0.01% 3115

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management's VTVT Position: Q2 2026 in Review

Vanguard Capital Management reduced its vTv Therapeutics (VTVT) stake by 13% in Q2 2026, selling an estimated $501K and leaving 94,463 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3232.

Vanguard Capital Management first reported a position in VTVT in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.32M in Q1 2026. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Vanguard Capital Management held 94,463 shares of vTv Therapeutics worth $3.56M as of Q2 2026.
  • Vanguard Capital Management sold 14,459 vTv Therapeutics shares in Q2 2026, an estimated $501K.
  • vTv Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3232 holding.
  • Vanguard Capital Management first reported a position in vTv Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's vTv Therapeutics position peaked at $4.32M in Q1 2026.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.